Servona GmbH

Servona GmbH specializes in transcervical artificial larynx devices, such as the SERVOX digital XL. These devices are specifically designed to help patients regain vocal function when they suffer from laryngeal disorders or vocal cord paralysis.

Servona GmbH is headquartered in the United States. The company’s location is relevant for regulatory compliance and device distribution, particularly in markets where local manufacturing or regional presence may influence approval pathways.

Servona GmbH’s devices, including the SERVOX digital XL, are listed in the FDA’s Unique Device Identifier (UDI) database. This registry ensures traceability and transparency in the medical device supply chain, helping healthcare providers verify device details and compliance.

Servona GmbH’s transcervical artificial larynx devices fall under FDA’s Class I classification. This classification is typically assigned to low-risk devices that pose minimal potential harm to patients, often requiring less stringent regulatory oversight compared to higher-risk categories.